Emerging basic research, preclinical and clinical findings support the importance of p70 S6 kinase (p70S6K), a downstream effector of mammalian target of rapamycin (mTOR), in the progression of ovarian cancer [2]. Here, MTOR is linked to ovarian carcinoma.